Jonathan Pachter
Chief Scientific Officer Verastem. inc
Seminars
Wednesday 9th September 2026
Mechanistically Differentiated KRAS G12D Inhibition: Advancing Novel Combination Strategies to Enhance Durability & Overcome Resistance
9:00 am
- Developing a mechanistically differentiated KRAS G12D inhibitor designed to achieve selective pathway suppression while addressing limitations observed with firstgeneration KRAS targeting approaches
- Exploring rational combination strategies that enhance antitumor activity and delay resistance through complementary pathway modulation
- Demonstrating compelling preclinical efficacy and translational insights supporting clinical advancement in KRAS G12D-driven tumors
